CervoMed Q3 2023 Earnings Report
Key Takeaways
CervoMed reported a net income of $2.2 million for the third quarter of 2023, driven by a noncash gain from the conversion of convertible notes upon the merger. The company's cash position is expected to fund operations through the end of 2024, with key data expected from the RewinD-LB trial.
Dosed first patient in Phase 2b RewinD-LB study evaluating neflamapimod in patients with dementia with Lewy bodies (DLB).
Multiple peer-reviewed journal publications and a conference presentation inform on the potential of neflamapimod in DLB and probability of success in optimized RewinD-LB study.
Completed reverse merger; company now publicly traded on Nasdaq (“CRVO”).
CervoMed has cash runway through the end of 2024, by which time the topline primary efficacy results from the Phase 2b RewinD-LB study are expected to be available.
CervoMed
CervoMed
Forward Guidance
CervoMed anticipates completing patient enrollment into the RewinD-LB Phase 2b clinical study in DLB in the first half of 2024 and reporting initial data from placebo-controlled portion of the RewinD-LB study during the second half of 2024